Found: 6
Select item for more details and to access through your institution.
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
- Published in:
- International Journal of Neuropsychopharmacology, 2017, v. 20, n. 8, p. 613, doi. 10.1093/ijnp/pyx033
- By:
- Publication type:
- Article
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
- Published in:
- International Journal of Neuropsychopharmacology, 2016, v. 19, n. 8, p. 1, doi. 10.1093/ijnp/pyw022
- By:
- Publication type:
- Article
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 3, p. 541, doi. 10.1002/alz.12035
- By:
- Publication type:
- Article
O4‐02‐03: RANDOMIZED TRIAL OF SUVOREXANT FOR TREATING INSOMNIA IN ALZHEIMER'S DISEASE: EFFECTS ON OBJECTIVE SLEEP MEASURES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1232, doi. 10.1016/j.jalz.2019.06.4748
- By:
- Publication type:
- Article
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
- Published in:
- Psychopharmacology, 2017, v. 234, n. 11, p. 1703, doi. 10.1007/s00213-017-4573-1
- By:
- Publication type:
- Article
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease.
- Published in:
- Journal of Sleep Research, 2021, v. 30, n. 6, p. 1, doi. 10.1111/jsr.13328
- By:
- Publication type:
- Article